
Gastroenterology
Pipeline
5 projects
(3 in clinical development)
Life Cycle
Normix, Tixteller, Xifaxan (rifaximin)
Fully developed by Alfasigma
Indicated for Hepatic Encephalopaty, Traveler’s diarrhea, IBS
Research & Innovation
While supporting existing assets and developing new indications to address unmet needs, our Research & Development Department is focused on three main therapeutic areas: gastroenterology, vascular disease & neuroscience disorders.
Our new strategic plan deals with next decades challenges in healthcare, leveraging opportunities in precision medicine, maximizing existing competencies in microbiome, acquiring new assets in late stage development.
We are partnering with other organizations to exploit new opportunities through big data, new technologies, and patient engagement projects.
Gastroenterology
5 projects
(3 in clinical development)
Vascular
1 project
Vessel (Sulodexide)
Fully developed by Alfasigma
Indicated for Venous disorders (CVI, rDVT), Arterial disorders (PAOD)
Neuroscience
New projects under assessment
Deplin (L-Methylfolate)
Indicated as Medical
Food for co-treatment
in Depressive
Disorders
Rifaximin
is one of the most effective microbiome modifier on the market
Irritable
Bowel Disease
Hepatic
Encephalopathy
Novel agents
Under exploration
You’re entering Alfasigma global website
I agree